ArticleEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026
The bleeding risk of low-molecular-weight heparin bridging therapy in patients receiving preoperative oral antithrombotic drugs during spinal fusion surgery.
Article in European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeTo evaluate whether preoperative oral antithrombotic therapy increases the perioperative bleeding tendency in patients undergoing spinal fusion with low-molecular-weight heparin (LMWH) bridging, and to compare their bleeding risk with that of a general surgical cohort.
methodsPatients undergoing spinal fusion (2019-2024) at two centers were categorized into three groups: (1) Oral Antithrombotics group (history of preoperative antithrombotic use with LMWH bridging), (2) No Oral Antithrombotics group (no preoperative antithrombotic history, receiving perioperative LMWH prophylaxis), and (3) Blank group (a 1:1 matched cohort without preoperative antithrombotic history or perioperative LMWH prophylaxis).
resultsThe Oral Antithrombotics group exhibited significantly higher intraoperative blood loss, increased transfusion rates, and longer hospital stays compared to the Blank group (p < 0.05). In the lumbar surgery subgroup, the Oral Antithrombotics group showed higher intraoperative and overt blood loss compared to the No Oral Antithrombotics group (p < 0.05), whereas no such differences were observed in cervical surgery.
conclusionWhile preoperative oral antithrombotic therapy with LMWH bridging does not raise the risk of severe bleeding events after spinal fusion, it correlates with an enhanced perioperative bleeding tendency, especially in lumbar fusion procedures.
Indexed as
Identifiers
42481767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.